MedTrace Logo

Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.

NCT02852954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-08-18

No results posted yet for this study

Summary

Immune system suppression effect of Progesterone Induced Blocking Factor(PIBF), it could be questionable whether tumor cells express PIBF for escape of immune system. There are some studies in the literature that evaluate PIBF expression of different malign cells (e.g. glioblastoma multiforme as a malign central nerve system, leukemia, astrocytoma as a primary brain tumor, lung cancer and chorionic carcinoma). According to previous studies PIBF has been used as an anti-tumor immune suppressor by tumor cells. There is no data about the PIBF expression of endometrial tumor cells. Therefore, the investigators aim to determine the PIBF expression levels in the endometrial cancer cells.

Conditions

  • Progesterone Induced Blocking Factor in Endometrial Cancer

Sponsors & Collaborators

  • Kayseri Education and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2016-12-31
Completion
2017-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02852954 on ClinicalTrials.gov